Vyome (NASDAQ:HIND) Announces Earnings Results

Vyome (NASDAQ:HIND) released its earnings results on Wednesday. The company reported ($0.10) EPS for the quarter, Zacks reports. The company had revenue of $0.27 million for the quarter.

Vyome Stock Performance

Shares of NASDAQ HIND traded up $0.02 during mid-day trading on Friday, reaching $2.18. The company had a trading volume of 2,324 shares, compared to its average volume of 356,025. The company has a market capitalization of $15.30 million, a price-to-earnings ratio of -0.18 and a beta of 1.48. The stock has a fifty day moving average of $2.17 and a two-hundred day moving average of $2.31. Vyome has a 12-month low of $1.75 and a 12-month high of $16.00.

Institutional Investors Weigh In On Vyome

An institutional investor recently bought a new stake in Vyome stock. Geode Capital Management LLC purchased a new position in Vyome Holdings, Inc. (NASDAQ:HIND) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,934 shares of the company’s stock, valued at approximately $41,000. Geode Capital Management LLC owned about 0.21% of Vyome at the end of the most recent quarter. 22.06% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on HIND. Zacks Research upgraded Vyome to a “hold” rating in a research report on Wednesday, May 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Vyome in a research report on Wednesday, July 29th. Finally, Litchfield Hills Research started coverage on shares of Vyome in a research report on Monday, May 4th. They issued a “buy” rating for the company. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Vyome Company Profile

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.